Quick Answer
Summit Therapeutics Inc. reported Stockholders Equity of $658.86 million for the year ending 2025.
- Summit Therapeutics Inc. showed an increase of +69.5% in Stockholders Equity from 2024 to 2025.
- This data is from Summit Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on February 23, 2026.
- XBRL data for this metric is available from 2018 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2018: $32.17 million | Q2 2019: $43.56 million | Q3 2019: $36.18 million | Q1 2020: $68.41 million | Q2 2020: $53.60 million | Q3 2020: $38.55 million | Q1 2021: $64.41 million | Q2 2021: $119.43 million | Q3 2021: $102.30 million | Q1 2022: $64.41 million | Q2 2022: $51.32 million | Q3 2022: $133.25 million | Q1 2023: $133.48 million | Q2 2023: $119.60 million | Q3 2023: $99.38 million | Q1 2024: $44.21 million | Q2 2024: $195.08 million | Q3 2024: $437.92 million | Q1 2025: $344.33 million | Q2 2025: $259.44 million | Q3 2025: $192.26 million.
- Over the full 9 years of available data (2018 to 2025), Summit Therapeutics Inc.'s Stockholders Equity has grown by 18,457.8%.
- Historical annual values: Fiscal year 2025: $658.86 million | Fiscal year 2024: $388.75 million | Fiscal year 2023: $77.69 million | Fiscal year 2022: $126.65 million | Fiscal year 2021: $83.28 million | Fiscal year 2020: $79.45 million | Fiscal year 2019: $78.86 million | Fiscal year 2019: $57.59 million | Fiscal year 2018: -$3.59 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: